#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.
GLP-1 Prescribing Without an Indication
A US records study of 92 million adults found GLP-1 prescribing without a documented indication rose 15-fold, and 35.1% of recipients had a normal BMI.
Semaglutide vs orforglipron: who paid?
A new indirect comparison says oral semaglutide beats orforglipron on weight loss. Five of its eight authors work for Novo Nordisk. Here is what it shows.
Orforglipron vs oral semaglutide in T2D
ACHIEVE-3 put the orforglipron pill head to head with the oral semaglutide pill in type 2 diabetes. Orforglipron won on HbA1c and lost on tolerability.
Semaglutide access and health inequity
Semaglutide works. Access does not follow need. Here is what fill-rate, pricing and policy data show about who actually gets treated, and who does not.
Semaglutide and wet AMD: signal vs proof
A 2026 study flagged semaglutide among five drugs with raised wet AMD reporting. Here is what that kind of signal can and cannot tell you.
Tirzepatide vs Semaglutide Side Effects
A new adverse-event reporting study compares tirzepatide and semaglutide, but raw report counts alone cannot show which drug is riskier.
What is food noise? Five theories
A 2026 Appetite review says food noise still has no settled definition. Here are the five theories behind it, and what the GLP-1 survey data shows.
What Obesity Drug Cost Models Show
A systematic review of economic evaluations finds anti-obesity medicine cost-effectiveness varies by setting, price, assumptions, and comparator.
Why a peptide list is not a treatment plan
A community peptide list can show what is being discussed, but it cannot establish safety, evidence or suitability for an individual.
GLP-1 Use After Bariatric Surgery
A retrospective cohort found no statistically significant weight-loss difference after bariatric surgery when GLP-1 medicines were started within a year.
Are healthcare systems ready for GLP-1s?
GLP-1 readiness requires continuity, transparent access rules and realistic expectations, not only an effective prescription.